+Compare
CMRX
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
86.45M

CMRX Chimerix Forecast, Technical & Fundamental Analysis

a developer of novel oral antiviral therapeutics

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for CMRX with price predictions
07:00 PM EST Dec 03, 2023

CMRX sees its Stochastic Oscillator climbs out of oversold territory

On December 01, 2023, the Stochastic Oscillator for CMRX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 62 instances where the indicator left the oversold zone. In of the 62 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 30, 2023. You may want to consider a long position or call options on CMRX as a result. In of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CMRX just turned positive on November 30, 2023. Looking at past instances where CMRX's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

CMRX moved above its 50-day moving average on December 01, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CMRX advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CMRX entered a downward trend on October 30, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.405) is normal, around the industry mean (20.645). P/E Ratio (0.471) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (74.074) is also within normal values, averaging (329.397).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CMRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 6%. For the same Industry, the average monthly price growth was 26%, and the average quarterly price growth was 26%. MMIRF experienced the highest price growth at 247%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -31%. For the same stocks of the Industry, the average monthly volume growth was -48% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

CMRX is expected to report earnings to fall 16.93% to -22 cents per share on February 29

Chimerix CMRX Stock Earnings Reports
Q4'23
Est.
$-0.22
Q3'23
Missed
by $0.04
Q2'23
Beat
by $0.03
Q1'23
Beat
by $0.01
Q4'22
Est.
$-0.24
The last earnings report on November 02 showed earnings per share of -27 cents, missing the estimate of -23 cents. With 280.47K shares outstanding, the current market capitalization sits at 86.45M.
A.I. Advisor
published General Information

General Information

a developer of novel oral antiviral therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2505 Meridian Parkway
Phone
+1 919 806-1074
Employees
89
Web
https://www.chimerix.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PURZX18.11N/A
N/A
PGIM Global Real Estate Z
JGRQX14.63N/A
N/A
JPMorgan Small Cap Growth R3
DLAKY8.96N/A
N/A
Deutsche Lufthansa A G
LTGHY3.92N/A
N/A
Life Healthcare Group Holdings Ltd
USGDF0.19N/A
N/A
American Pacific Mining Corp

CMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CMRX has been loosely correlated with AVIR. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CMRX jumps, then AVIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMRX
1D Price
Change %
CMRX100%
-2.92%
AVIR - CMRX
47%
Loosely correlated
-3.53%
VCYT - CMRX
44%
Loosely correlated
-1.77%
BEAM - CMRX
43%
Loosely correlated
-0.03%
VXRT - CMRX
43%
Loosely correlated
+0.29%
CRSP - CMRX
43%
Loosely correlated
+4.17%
More

Groups containing CMRX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMRX
1D Price
Change %
CMRX100%
-2.92%
drugs
(undefined stocks)
48%
Loosely correlated
+1.61%
biotechnology
(undefined stocks)
47%
Loosely correlated
+1.96%
therapeutics
(undefined stocks)
46%
Loosely correlated
+3.03%
oral products
(undefined stocks)
21%
Poorly correlated
-0.36%